SODIUM LACTATE IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SODIUM LACTATE IN PLASTIC CONTAINER (SODIUM LACTATE IN PLASTIC CONTAINER).
Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.
| Metabolism | Metabolized in the liver via lactate dehydrogenase and the Cori cycle to bicarbonate and glucose. |
| Excretion | Sodium lactate is metabolized to bicarbonate in the liver via the Cori cycle; less than 5% is excreted unchanged in urine under normal conditions. Biliary/fecal elimination is negligible. |
| Half-life | The terminal elimination half-life of lactate is approximately 5–10 minutes due to rapid hepatic metabolism; this short half-life allows quick correction of metabolic acidosis when administered intravenously. |
| Protein binding | Minimal protein binding (<5%) as lactate is a small, water-soluble molecule; not significantly bound to plasma proteins. |
| Volume of Distribution | Volume of distribution approximates total body water (0.5–0.6 L/kg) because lactate distributes freely into the extracellular and intracellular spaces; this reflects its rapid equilibration. |
| Bioavailability | Intravenous: 100% (administered directly into the bloodstream). Oral: Not clinically used; oral administration is not bioavailable as lactate is metabolized in the gut and liver first-pass. |
| Onset of Action | Intravenous: Onset of alkalinizing effect occurs within minutes, typically 5–15 minutes after infusion begins, as lactate is converted to bicarbonate. |
| Duration of Action | The alkalinizing effect lasts 1–2 hours post-infusion, depending on the patient's metabolic rate and acid-base status; continuous infusion may be required for sustained effect. |
Intravenous (IV) infusion: Initial dose 300-500 mL of 1/6 M (M/6) sodium lactate solution (167 mEq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min) due to risk of fluid overload and hypernatremia; for GFR 30-59 mL/min, use with caution and reduce infusion rate by 50%. |
| Liver impairment | Child-Pugh Class A: No adjustment; Class B: Use with caution, reduce dose by 25%; Class C: Avoid use due to impaired lactate metabolism. |
| Pediatric use | Neonates and infants: 4.5 mL/kg of M/6 sodium lactate IV over 1 hour; children: 20-30 mL/kg of M/6 sodium lactate IV at a rate not exceeding 10 mL/kg/hour, titrated to monitoring of acid-base status. |
| Geriatric use | Elderly patients: Start at low end of dosing range, monitor for fluid overload, hypernatremia, and metabolic alkalosis; infusion rate not to exceed 100 mL/hour due to reduced cardiac and renal reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SODIUM LACTATE IN PLASTIC CONTAINER (SODIUM LACTATE IN PLASTIC CONTAINER).
| Breastfeeding | Sodium lactate is a normal constituent of plasma and breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio is not established but expected to be near 1. It is considered compatible with breastfeeding. |
| Teratogenic Risk | Sodium lactate is used as an intravenous electrolyte replenisher and alkalizing agent. Data on teratogenic risk are limited. In animal studies, sodium lactate did not show fetal harm at doses within clinical range. However, no well-controlled human studies exist. The risk is considered low but cannot be excluded. Use in pregnancy only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Severe metabolic alkalosis","Hypernatremia (if sodium-containing)","Lactic acidosis not due to correctable causes"]
| Precautions | ["Use with caution in patients with lactic acidosis if etiology is not correctable","Monitor serum electrolytes, acid-base status, and fluid balance","Risk of fluid overload in patients with heart failure or renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, acid-base status, fluid balance, and renal function. Fetal heart rate monitoring is recommended in high-risk pregnancies or when large volumes are infused. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available. |